SCHEMBL4884655

SCHEMBL4884655

COc1cccc(CNC(=O)c2ccc3ncnc(Nc4ccc(N5CCOCC5)cc4)c3c2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STAT6 P42226 1/20 0.54
MAPT P10636 2/20 0.52
MAPK1 P28482 1/20 0.52
AHR P35869 1/20 0.52
HTT P42858 1/20 0.52
KDM4E B2RXH2 1/20 0.51
POLB P06746 1/20 0.51
MAPK14 Q16539 1/20 0.50
MMP13 P45452 2/20 0.49
PI4KB Q9UBF8 1/20 0.49
PDGFRB P09619 1/20 0.48
FLT4 P35916 1/20 0.48
AURKA O14965 1/20 0.48
AURKB Q96GD4 1/20 0.48
CDK2 P24941 1/20 0.47
FLT3 P36888 1/20 0.47
CCNA1 P78396 1/20 0.47
ABCB1 P08183 1/20 0.47
ABCG2 Q9UNQ0 1/20 0.47
GMPS P49915 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4890691 0.91 MAPT (0.55) MAPTMAPK1AHRHTTMAPK14
SCHEMBL4882893 0.85 MAPT (0.57) MAPTMAPK1AHRHTTKDM4E
SCHEMBL4891765 0.83 MAPT (0.63) MAPTMAPK1AHRHTTKDM4E
SCHEMBL4888741 0.80 MAPT (0.67) MAPTMAPK1AHRHTTKDM4E
SCHEMBL4891326 0.78 PI4KB (0.54) MAPTMAPK1AHRHTTMAPK14
SCHEMBL4890194 0.77 MAPT (0.71) MAPTMAPK1AHRHTTKDM4E
SCHEMBL4884795 0.77 MAPT (0.61) MAPTMAPK1AHRHTTKDM4E
SCHEMBL4888073 0.76 MAPK1 (0.66) MAPTMAPK1AHRHTTPOLB
SCHEMBL4890620 0.72 EGFR (0.71) MAPTMAPK1AHRHTTAURKA
SCHEMBL14026144 0.71 MAPT (0.77) MAPTMAPK1AHRHTTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080311076-A1 Morpholinylanilinoquinazoline Derivatives For Use As Antiviral Agents ARROW THERAPEUTICS LIMITED (GB) 2008-12-18 US disclosed
EP-1748991-A1 MORPHOLINYLANILINOQUINAZO- LINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS Arrow Therapeutics Limited (GB) 2007-02-07 EP disclosed
WO-2005105761-A1 MORPHOLINYLANILINOQUINAZO- LINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS ARROW THERAPEUTICS LIMITED (GB) 2005-11-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080311076-A1 Morpholinylanilinoquinazoline Derivatives For Use As Antiviral Agents EIF2AK2, MAVS, IRF3 STAT6 1593/4885MAPT 2064/4885MAPK1 1945/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.